HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

[Endovascular treatment of intracranial arteriovenous malformation with n-butyl cyanoacrylate. Working methods and experience in 58 cases].

AbstractBACKGROUND AND PURPOSE:
Arteriovenous malformations (AVMs) constitute malformative lesions of the central nervous system vasculature and cause significant morbidity and mortality. Endovascular embolization with n-butyl cyanoacrylate is a well established modality of AVM treatment, usually combined with surgery or radiosurgery. The purpose of this study was to characterise the AVMs that were treated endovascularly with n-butyl cyanoacrylate and to evaluate the post-embolization results in the Cuban population.
MATERIALS AND METHODS:
From February 2006 to February 2011, a group of 58 consecutive patients with brain AVMs were embolized using n-butyl cyanoacrylate in the endovascular therapy unit of the Medical Surgical Research Centre in Havana (Cuba). In all, 91sessions were carried out with intranidal embolization and mainly partial devascularization, 25-30% per session, and closing 123 arterial pedicles. Safety times for n-butyl cyanoacrylate injection were established by calculating the polymerisation times for different dilutions, using post-embolisation hypotension systematically, as well as a superselective test with propofol to determine cerebral eloquence.
RESULTS:
Haemorrhagic signs were the initial presentation in 68.8% of the patients, 24.1% presented with epileptic episodes and 1.7% with ischemic stroke. Of the AVMs, 93.2% were supratentorial; according to the Spetzler and Martin classification, 13.8% were grade II, 56.9% were grade III, 22.4% were grade IV and 6.8%, grade V. One hundred and twenty-eight selective tests with propofol were performed and 118 (92.2%) of those were negative. Partial devascularization (20-30%) prevailed; complete obliteration was achieved in 17.2% of the patients and 70%-99% in 27.5% of the patients. Safety times for n-butyl cyanoacrylate injection were established and the use of post-procedure hypotension was settled. Morbidity of 17.2%, with 6.9% haemorrhagic complications and mortality of 3.4% were registered in the whole series.
CONCLUSIONS:
The rates of total occlusion and of morbidity and mortality in the series are in the internationally described ranges. The implementation of intranidal closings with 20-30% devascularization per session and the use of post-embolization hypotension after the haemorrhage complications described resulted in the total absence of haemorrhagic complications.
AuthorsJosé A Jordan González, Juan Carlos Llibre Guerra, José A Prince López, Frank Vázquez Luna, Raúl Marino Rodríguez Ramos, José Carlos Ugarte Suarez
JournalNeurocirugia (Asturias, Spain) (Neurocirugia (Astur)) 2013 May-Jun Vol. 24 Issue 3 Pg. 110-20 ISSN: 1130-1473 [Print] Spain
Vernacular TitleTratamiento endovascular de malformaciones arteriovenosas intracerebrales con n-butil cianoacrilato. Métodos de trabajo y experiencia en 58 casos.
PMID23566543 (Publication Type: Journal Article)
CopyrightCopyright © 2012 Sociedad Española de Neurocirugía. Published by Elsevier España. All rights reserved.
Chemical References
  • Tissue Adhesives
  • Enbucrilate
  • Propofol
Topics
  • Adolescent
  • Adult
  • Aged
  • Brain Ischemia (etiology)
  • Cerebral Angiography
  • Child
  • Embolization, Therapeutic (adverse effects, methods)
  • Enbucrilate (therapeutic use)
  • Endovascular Procedures
  • Epilepsy (etiology)
  • Female
  • Humans
  • Intracranial Arteriovenous Malformations (complications, diagnostic imaging, therapy)
  • Intracranial Hemorrhages (etiology)
  • Intracranial Hypotension (etiology)
  • Male
  • Middle Aged
  • Propofol
  • Tissue Adhesives (therapeutic use)
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: